Diberdayakan oleh Blogger.

Popular Posts Today

ECB launches major review of banks

Written By Unknown on Rabu, 23 Oktober 2013 | 23.14

FRANKFURT, Germany — The European Central Bank is launching a review of 128 of the eurozone's biggest banks, a push to restore faith in the financial system — and lay the groundwork for growth — after similar studies fell short.

The review will be a key test of the ECB's credibility as it prepares to take over as the European Union's banking supervisor. Previous stress tests carried out in 2009 and 2011 by another agency with more limited powers, the European Banking Authority, cleared several banks that were in need of rescuing soon after.

Europe's slow progress in cleaning up the banks contrasts with the United States. There, officials moved early to make banks strengthen their financial buffers in the wake of the 2008 collapse of investment bank Lehman Brothers.

The ECB announced Wednesday that its review of the banks will begin next month and take a year. Working with national regulators, ECB officials will take a broad look at the banks' holdings and financial strength. In particular, they will look for hidden losses such as loans to businesses and real estate projects that are unlikely to be repaid.

ECB President Mario Draghi called it "an important step forward for Europe and for the future of the euro area economy."

The ECB's review will be followed by a stress test that would simulate bank losses in a sudden economic downturn or financial crisis, conducted along with the European Banking Authority.

The question is whether that stress test will be more credible than the previous ones.

Thomas Huertas, a partner in a unit of Ernst & Young, said they probably would because the ECB will have already reviewed the banks' balance sheets before conducting the test — something the EBA was not able to do before.

At the end, banks could be pushed to repair their finances by raising more capital or selling off risky holdings.

The issue is import for Europe's recovery because banks that are holding soured investments, such as bad loans, may be unable or unwilling to find cash to lend to businesses that need credit to expand their operations. They may also be asking for higher interest rates to lend, blunting the ECB's ability to stimulate the economy with lower borrowing costs.

The eurozone grew only 0.2 percent in the second quarter after contracting for six quarters and unemployment remains high at 12 percent.

The asset review and stress test need to be done before the ECB takes over as the European Union's banking supervisor next year. The single supervisor is part of a broader effort to strengthen the financial system and prevent a repeat of the debt problems afflicting countries such as Spain and Ireland, where bank bailouts hurt government finances.

Ignazio Angeloni, an ECB official, said the result would call for "repair where repair is necessary" and won't necessarily include a figure for raising new capital.

The ECB's job may be complicated by the fact that Europe does not yet have a single authority to restructure or shore up banks that review identifies as weak. European leaders are still debating how to set up such an authority. If banks cannot raise new capital from private investors, they could turn to their national authorities. Under some circumstances, the eurozone's bailout fund could be used, but the idea has faced stiff political resistance from governments.


23.14 | 0 komentar | Read More

China banking worries weigh on markets

LONDON — Worries over the Chinese banking sector weighed on markets Wednesday, a day after weak U.S. jobs data reinforced expectations that the Federal Reserve won't be reducing its monetary stimulus anytime soon.

Tuesday's news that the U.S. generated only 148,000 jobs in September, below the consensus among analysts for around 180,000, prompted stocks in Europe and the U.S. to rally. However, that momentum came to a grinding halt during the Asian trading session amid concerns over the bad loans that are being written off by China's largest banks.

"This has reignited fears over China's shadow banking system and whether the People's Bank of China will be forced to raise interest rates in order rein in it," said Craig Erlam, market analyst at Alpari. "If we do see a tightening of monetary policy, it could choke off the recovery being seen in the world's second largest economy, which in turn would impact growth globally."

In Europe, the FTSE 100 index of leading British shares was down 0.5 percent at 6,661 while Germany's DAX fell the same rate to 8,902. The CAC-40 in France was 1 percent lower at 4,254.

In the U.S., the Dow Jones industrial average was down 0.7 percent at 15,369 while the broader S&P 500 index fell 0.7 percent to 1,742.

A mixed bag of U.S. corporate earnings did little to alter the prevailing profit-taking mood. While Caterpillar's quarterly earnings plunged 44 percent and the company cut its outlook for the year again, Boeing's shares were well supported after beating analyst expectations.

A solid earnings season has been one reason why the S&P has hit a series of record highs, along with delayed expectations of when the Fed will begin "tapering" its stimulus.

Max Cohen, a trader at Spreadex, says earnings have beaten analyst estimates at 74 percent of the 141 companies of the S&P that have released their results so far, while 53 percent exceeded sales projections.

Elsewhere, the dollar consolidated, particularly against the euro, after falling back in the wake of the payrolls figures — the euro was flat at $1.3773, just shy of its near two-year high of $1.3793.

Earlier in Asia, China's Shanghai Composite Index fell 1.3 percent to 2,183.11 and Hong Kong's Hang Seng shed 1.4 percent to 23,999.95. Japan's Nikkei 225 tumbled 2 percent to 14,426.05 as the yen gained against the U.S. dollar, which can hurt sales and profits at Japanese exporters. Australia's S&P/ASX 200 fell 0.3 percent to 5,356.10.

Oil prices remained under pressure too, with the benchmark New York rate down $1.75 at $96.56 a barrel — near its lowest level since late June. Ample supplies, worries over the U.S. economy, and an easing of geopolitical tensions relating to Iran and Syria have weighed on oil prices in recent weeks.


23.14 | 0 komentar | Read More

FDA issues positive review for Gilead's hep C drug

WASHINGTON — The Food and Drug Administration has issued a positive review for a highly anticipated hepatitis C drug from Gilead Sciences, saying the pill cures more patients in less time than currently available treatments.

The agency posted its review of Gilead's sofosbuvir online ahead of a meeting Friday where government experts will vote on whether to recommend the drug's approval.

More than 3 million people in the U.S. have hepatitis C, a blood-borne disease that causes liver damage and is blamed for 15,000 deaths a year. The drugs currently used to treat the virus cure about three-quarters of people and can take up to a year of treatment.

FDA said adding Gilead's sofosbuvir to the standard drug cocktail cured 90 percent of patients with the most common form of the virus in just 12 weeks.

The agency's reviewers state that the "shorter 12-week duration translates into a better tolerated side effect profile," adding that "no major safety issues associated with sofosbuvir have been identified to date."

Foster City, Calif.-based Gilead Sciences is one of a half-dozen drugmakers working to develop more effective treatments for hepatitis C, though many analysts predict the company's drug will eventually outperform its competitors. The FDA is expected to make a decision on the drug by Dec. 8.

Drugmakers see hepatitis treatments as a potentially lucrative market because the disease is expected to grow into a major public health problem as the baby boom generation ages. People born between 1945 and 1965 are five times more likely to have the virus than people of other age groups, and the Centers for Disease Control and Prevention is urging all baby boomers to get tested for the disease. Many Americans contracted the virus by sharing needles or having sex with an infected person in their youth.

For most of the last 20 years, the standard treatment for hepatitis C has involved a grueling one-year regimen of pills and injections that caused flu-like symptoms and cured less than half of patients. Then in 2011, the FDA approved two new drugs from Merck and Vertex Pharmaceuticals that raised the cure rate to about 65 and 75 percent, respectively, when combined with the older treatments.

Gilead's once-a-day pill appears to push the cure rate even higher.

In a company study of 327 patients with the most common form of the disease, 90 percent of participants had undetectable levels of the virus after 12 weeks of treatment. The form of the disease studied in the trial accounts for about 75 percent of hepatitis C cases in the U.S.

Gilead's drug was not as effective in treating two less common forms of the disease that account for about 25 percent of cases in the U.S. Among those patients, sofosbuvir cured about 67 percent of patients who had not previously taken other hepatitis C drugs.

But even for those patients, the FDA says Gilead's drug represents an important step forward.

The company's approach used only pill-based medications — sofosbuvir and another antiviral drug — while excluding interferon, the injectable medication that is the backbone of standard treatment, which can cause nausea, diarrhea and other unpleasant side effects.

For patients with the less common subtypes of the disease, Gilead's approach "provides the first all-oral, interferon-free treatment, as well as a shorter treatment duration and improved safety profile," according to the FDA's review.

Gilead is racing against other drugmakers to develop the first all-pill approach to treating the most common form of hepatitis C, long viewed as the holy grail of treatments by drugmakers. Similar efforts are underway from Abbott Laboratories, Bristol-Myers Squibb Co., Vertex Pharmaceuticals and others.

Pharmaceutical industry consulting firm Decision Resources estimates the market for hepatitis C drugs will grow to more than $23 billion by 2018. Sales of the drugs are expected to decline to $17.5 billion by 2021 as more patients are cured of the virus.

Shares of Gilead Sciences Inc. rose $1.01 to $69.10 in morning trading.


23.14 | 0 komentar | Read More

FedEx expects increase in holiday deliveries

MEMPHIS, Tenn. — FedEx expects that holiday shoppers will be more nice than naughty this year, with shipments rising from 2012.

The company said Wednesday that it expects to carry more than 22 million shipments on the busiest day of the season, which it believes will be Monday, Dec. 2.

FedEx predicts that shipments in the first week of December will rise 13 percent over last year's peak week, to more than 85 million shipments, driven by online shopping and retailers stocking up on electronics, apparel and other goods.

The expected top day, Dec. 2, will be the first work day for many shoppers after the long Thanksgiving weekend. This is the first time that FedEx expects so-called "Cyber Monday" to be its busiest day of the season.

Last year, the company's heaviest load fell on Dec. 17, when it carried 19.9 million shipments. It also saw spikes of 19.6 million shipments on Cyber Monday and 19 million on Dec. 10.

If FedEx's forecast is correct, the 2013 peak day will be roughly double the volume of its busiest day just six years ago.

The National Retail Federation predicts that retail sales in November and December will rise 3.9 percent over last year to $602 million — $738 per shopper. It expects online sales to rise by 13 percent to 15 percent.

FedEx, United Parcel Service Co. and others will fight over all those deliveries. This week, FedEx rolled out a new service called One Rate, a flat-rate shipping option that it hopes will boost its share of the holiday-shipping business. This spring, it offered a service that allows residential recipients to schedule deliveries.

Memphis-based FedEx Corp. expects to hire slightly more than the 20,000 seasonal workers that it added last year.

In morning trading, FedEx shares fell $1.01 to $128.68.


23.14 | 0 komentar | Read More

Starbucks to open 'tea bar' in New York City

NEW YORK — Starbucks is trying to make tea trendy, with plans to open its first "tea bar" in New York City.

The Seattle-based company says Teavana Fine Teas + Teavana Tea Bar will serve sweets and other food including flatbreads, salads and small plates ranging in price from about $3 to $15.

It is a switch for the Teavana chain to offer Starbucks-style freshly made drinks and food. Its stores are primarily in shopping malls and sell boxed and loose tea and accessories.

Drink prices will range from $3 to $6, and include novelties such as a Spiced Mandarin Oolong tea and a Pineapple Kona Pop + Blueberry Bliss iced tea.

Starbucks opened a similar tea shop last year near its headquarters under its Tazo brand. Next month, that store will be converted into a Teavana tea bar as well.

The opening of the New York City store on Thursday comes after Starbucks last year bought Teavana, a chain of about 300 stores. Starbucks has said it plans to use the acquisition to make tea a bigger part of American culture, as it has with coffee.

Starbucks Corp., which has about 11,000 U.S. locations, has been on a strong financial run even in the weak economy, boosting its profits by raising prices, revamping food offerings and adding items such as pricey bottled juices. In its latest quarter, it said sales rose 9 percent at cafes open at least a year.

The idea of a tea shop isn't new, of course. Jenny Ko, a part owner of the Culture Tea Bar in New York's Harlem neighborhood, notes that they're more prevalent on the West Coast but that they've been popping up on the East Coast more recently as well.

Ko said she welcomes Starbucks' push into tea shops, even though the company has put many put many smaller coffee chains out of business with the popularity of its namesake stores. She said she thinks her tea shop has enough unique offerings to withstand the competition. Besides, she said Starbucks' push should lead to greater awareness about teas in general.

"That's how everyone got into coffee, after Starbucks opened," Ko said.

Already, Ko noted people are more knowledgeable about tea, with customers increasingly familiar with different varieties such as oolong and Darjeeling.

___

Follow Candice Choi at www.twitter.com/candicechoi.


23.14 | 0 komentar | Read More

GSK sales in China tumble amid bribery probe

LONDON — GlaxoSmithKline says its sales of drugs and vaccines in China tumbled in the third quarter as it was hit by bribery investigations there.

Worldwide sales, it says, were flat as growth in the U.S. and Europe helped offset China's 61 percent drop. Total revenue rose 1 percent to 6.51 billion pounds ($10.5 billion).

The company was hit by allegations by the Chinese government that four of its employees paid bribes to doctors and hospitals to encourage them to prescribe medications.

Chief Executive Andrew Witty said Wednesday that the decline in China was disappointing but it was too early to judge the long-term impact of the probe.

The company said it expected earnings per share to grow between 3 percent and 4 percent this year.


23.14 | 0 komentar | Read More

Nissan recalls over 188,000 SUVs to fix brakes

DETROIT — Nissan Motor Co. is recalling more than 188,000 Nissan and Infiniti SUVs worldwide to fix faulty brake control software that could increase the risk of a crash.

The recall covers some Nissan Pathfinders from the 2013 and 2014 model years, as well as the 2013 Infiniti JX35 and its successor model, the 2014 QX60.

Nissan says that during light braking on rough roads, the antilock brake software could cause longer-than-expected stopping distances. The company said no crashes or injuries have been reported.

Nissan will notify owners within 60 days, and dealers will reprogram the antilock brakes free of charge.

The recall includes nearly 152,000 SUVs in the U.S. and roughly 36,000 in China, Canada, Mexico and other countries, the company said.

The Pathfinders were built between April 18, 2012 and Sept. 20 of this year. The JX35s were built from Sept. 15, 2011 to Jan. 16 of this year, while the QX60s were built from Jan. 17 to Sept. 20 of this year.

Owners with questions can contact Nissan at (800) 647-7261.


23.14 | 0 komentar | Read More

WellPoint's 3Q profit falls 5 pct, forecast climbs

INDIANAPOLIS — WellPoint Inc.'s third-quarter earnings fell 5 percent but still topped expectations, and the nation's second-largest health insurer said it raised its 2013 forecast despite added expenses from the health care overhaul.

The Blue Cross Blue Shield insurer said Wednesday its performance so far this year helped prompt it to raise its forecast for 2013 adjusted earnings to at least $8.40 per share. That's up from its previous forecast for at least $8 per share and well beyond the $8.26 per share average that analysts surveyed by FactSet expect.

Company executives told analysts they are doing this despite making sizeable investments to get ready for upcoming coverage expansions under the overhaul.

The law aims to provide health insurance coverage to millions of uninsured people, and it took a major step toward that goal on Oct. 1, when enrollment started for coverage that begins Jan. 1. The overhaul calls for an expansion of the state-federal Medicaid program and also provides income-based tax credits to help people buy coverage on health insurance exchanges that are set up in each state.

WellPoint is selling coverage on several of these exchanges. Chief Financial Officer Wayne DeVeydt said WellPoint has spent about $300 million to prepare for the exchanges, and they expect to spend $70 million to $100 million on marketing for coverage the insurer sells on them.

Analysts and investors expect the overhaul's coverage expansion to affect WellPoint more than other insurers because the company derives a large portion of its business from the individual market and through smaller employers who cover their workers. Investors haven't been sure how much business insurers like WellPoint will lose or gain because of these exchanges.

They'll have to wait a little longer to get clarity on that. Computer glitches tied to the largely online exchanges have frustrated consumers in many states as they have tried to shop around for coverage.

DeVeydt said the insurer has enrolled people through the exchanges, but they don't have a clear picture yet on how many because they haven't received all the paperwork for those customers.

Overall, WellPoint said it earned $656.2 million, or $2.16 per share, in the quarter that ended Sept. 30. That compares to $691.2 million, or $2.15 per share, last year, when the company had more shares outstanding. Earnings excluding one-time items totaled $2.10 per share.

Analysts expected, on average, earnings of $1.81 per share, according to FactSet.

Operating revenue, which excludes investment gains or losses, soared 17 percent to $17.73 billion and topped analyst expectations for $17.66 billion.

WellPoint shares fell 3.5 percent, or $3.13, to $85.32 in midday trading Wednesday, while the Standard & Poor's 500 index dropped less than 1 percent.


23.14 | 0 komentar | Read More

176-year-old Fall River business closing

FALL RIVER, Mass. — A 176-year-old Fall River masonry supply business is shutting down, a victim of the changing face of the city.

Owner Winthrop Sanford says Building Materials Inc. will close for good on Oct. 31. It specializes in bricks, mortar and stone.

He tells the Herald News (http://bit.ly/163BFNE ) he has seen the business's demise coming for years, as the city's mills closed and retail customers moved to the suburbs.

He says there used to be 40 to 50 masons in the city. Now there are four or five.

The company was founded in 1837 and has been in Sanford's family since 1900.

At its height right after World War II, the company employed about 40 people. In the last decade it has had six to eight employees.

___

Information from: The (Fall River, Mass.) Herald News, http://www.heraldnews.com


23.14 | 0 komentar | Read More

Ex-Utah Gov. Huntsman hosting weekly radio show

SALT LAKE CITY — Former Republican Utah Gov. Jon Huntsman, a 2012 presidential candidate, will be hosting a new weekly radio talk show on SiriusXM satellite radio aimed at promoting bipartisan politics.

Huntsman helped launch a similar program in May, but that show was monthly and Huntsman only served as an occasional host.

SiriusXM says in a statement that the company felt the monthly show was a success and decided to expand it to a weekly program with Huntsman.

The new venture, an hour-long program called "No Labels Radio with Jon Huntsman," will air on Saturdays, starting on Oct. 26.

Huntsman is a co-chair of a group of 87 members of Congress called No Labels, which calls for an end to dysfunctional politics and more problem-solving in Washington, D.C.


23.14 | 0 komentar | Read More
techieblogger.com Techie Blogger Techie Blogger